Work on High-Speed Vaccine Factories Prompts Questions

Global Security Newswire Staff
Add to Briefcase
Global Security Newswire Staff
April 30, 2014, 9:49 a.m.

Spe­cial­ists are ques­tion­ing the feas­ib­il­ity of three U.S. factor­ies be­ing built to rap­idly turn out drugs needed after an at­tack or dis­aster, Nature re­ports.

Cer­tain ana­lysts ar­gued that few use­ful an­ti­dotes are cur­rently avail­able for re­spond­ing to the types of bio­lo­gic­al and chem­ic­al events en­vi­sioned by the pro­duc­tion fa­cil­it­ies un­der pre­par­a­tion in Texas, North Car­o­lina and Mary­land, the journ­al re­por­ted on Tues­day. Ob­serv­ers also cast doubt on the util­ity of next-gen­er­a­tion small­pox vac­cines, as well as oth­er drugs that may be pro­duced at the so-called Cen­ters for In­nov­a­tion in Ad­vanced De­vel­op­ment and Man­u­fac­tur­ing.

The United States is re­l­at­ively un­likely to face a chem­ic­al or bio­lo­gic­al strike for which the factor­ies would prove use­ful, ar­gued Richard Ebright, a mo­lecu­lar bio­lo­gist with Rut­gers Uni­versity. The Texas plant is slated to be­gin gen­er­at­ing its first vac­cine in the middle of this year, and fed­er­al of­fi­cials plan in the next quarter-cen­tury to spend up to $2 bil­lion on med­ic­al treat­ments from that single fa­cil­ity.

Philip Rus­sell, a former biode­fense ad­viser for the George W. Bush ad­min­is­tra­tion, sug­ges­ted the United States should have built just one such pro­duc­tion site for ci­vil­ian and mil­it­ary needs, in line with a 2008 re­com­mend­a­tion by the Pentagon’s De­fense Ad­vanced Re­search Pro­jects Agency.

“Rather than one good op­er­a­tion that meets the gov­ern­ment’s needs, we got three op­er­a­tions that spread the money around,” Rus­sell said of the $440 mil­lion ini­ti­at­ive, launched in 2012 by the Health and Hu­man Ser­vices De­part­ment.

The cur­rent plan’s back­ers, mean­while, ar­gued that op­er­at­ing sev­er­al man­u­fac­tur­ing plants would provide a fall­back if one is com­prom­ised by a strike or re­lease of haz­ard­ous ma­ter­i­al.

In ad­di­tion to the three sites over­seen by Health and Hu­man Ser­vices, the De­fense De­part­ment is con­struct­ing a $136 mil­lion fact­ory in Flor­ida to gen­er­ate smal­ler quant­it­ies of biode­fense products for armed-forces use. That site is ex­pec­ted to op­er­ate at an an­nu­al cost of $20 mil­lion fol­low­ing its sched­uled launch in 2015.

What We're Following See More »
TO BE VOTED ON NEXT MONTH
Pai Officially Announces Intent to Scrap Net Neutrality Rules
1 hours ago
THE LATEST
SAYS HE’S UNAWARE OF ACCUSATIONS
Conyers Denies Settling Harassment Claims
1 hours ago
THE LATEST
SPEAKER SAYS IN LETTER
Mugabe Resigns, Ending Impeachment Debate
1 hours ago
THE LATEST
HAITIANS TO BE MOST AFFECTED
White House to End TPS Program
1 hours ago
THE DETAILS

"The Trump administration is ending a humanitarian program that has allowed some 59,000 Haitians to live and work in the United States since an earthquake ravaged their country in 2010, Homeland Security officials said on Monday. Haitians with what is known as Temporary Protected Status will be expected to leave the United States by July 2019 or face deportation. ... About 320,000 people now benefit from the Temporary Protected Status program, which was signed into law by President George Bush in 1990."

Source:
MAKES PERMANENT A PREVIOUS INJUNCTION
Federal Judge Blocks Sanctuary Cities Order
2 hours ago
THE LATEST

"A federal judge on Monday permanently blocked President Donald Trump's executive order to cut funding from cities that limit cooperation with U.S. immigration authorities. U.S. District Court Judge William Orrick rejected the administration's argument that the executive order applies only to a relatively small pot of money and said Trump cannot set new conditions on spending approved by Congress. The judge had previously made the same arguments in a ruling that put a temporary hold on the executive order."

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login